RECORDATI |
Market Closed -
Other stock markets
|
After market 01:41:51 pm | |||
| 51.2 EUR | +1.39% |
|
51.22 | +0.05% |
| 10:04am | MIb down; Leonardo bats a path after accounts | AN |
| May. 07 | Mib in green; UniCredit and MPS boost profit | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.3B 2.47B | Sales 2025 * | 2.44B 2.62B | Capitalization | 10.39B 11.17B |
|---|---|---|---|---|---|
| Net income 2024 * | 477M 513M | Net income 2025 * | 523M 562M | EV / Sales 2024 * | 5.09 x |
| Net Debt 2024 * | 1.31B 1.41B | Net Debt 2025 * | 1.08B 1.17B | EV / Sales 2025 * | 4.71 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
20.3
x | Employees | 4,455 |
| Yield 2024 * |
2.79% | Yield 2025 * |
3.06% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
| 1 day | +1.09% | ||
| 1 week | +1.69% | ||
| Current month | +2.00% | ||
| 1 month | +2.26% | ||
| 3 months | +1.17% | ||
| 6 months | +16.55% | ||
| Current year | +4.55% |
1 week
49.88
51.35
1 month
48.3853.40
Current year
47.2953.40
1 year
40.6253.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 51.2 | +1.39% | 251 598 |
| 24-05-07 | 50.5 | +0.30% | 299,746 |
| 24-05-06 | 50.35 | -0.79% | 129,287 |
| 24-05-03 | 50.75 | +1.10% | 257,183 |
| 24-05-02 | 50.2 | +0.30% | 282,441 |
Real-time Borsa Italiana, May 08, 2024 at 07:19 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
50.5
EUR
Average target price
52.14
EUR
Spread / Average Target
+3.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.55% | 11.2B | |
| +33.43% | 700B | |
| +27.78% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +15.94% | 236B | |
| +6.73% | 202B | |
| -9.45% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- REC Stock